Table 1.
Baseline Patient Characteristics.
| GROUP 1 EUS-Guided Liver Biopsy (54 pts) |
GROUP 2 Percutaneous Liver Biopsy (62 pts) |
p Value | |
|---|---|---|---|
| Age (years) | 0.24 | ||
| median (IQR) | 56 (48, 69) | 54 (45, 67) | |
| Gender | 0.82 | ||
| Male | 32 (59.2%) | 38 (61.2%) | |
| Female | 22 (40.8%) | 24 (38.8%) | |
| Biopsy | 1.0 | ||
| Focal lesion | 27 (50%) | 31 (50%) | |
| Parenchymal disease | 27 (50%) | 31 (50%) | |
| Lesion size (mm) * | 0.83 | ||
| Median (IQR) | 17 (11–22) | 18 (13–23) | |
| Liver cirrhosis | 0.82 | ||
| yes | 27 (50%) | 38 (61.2%) | |
| no | 27 (50%) | 24 (38.8%) | |
| Total bilirubin (mg/dL) | 0.45 | ||
| median (IQR) | 0.7 (0.5–1.4) | 1.1 (0.5–1.5) | |
| Aspartate aminotransferase (UI/dL) | 0.58 | ||
| median (min, max) | 31.3 (15–260) | 42.4 (25–302) | |
| Alanine aminotransferase (UI/dL) | 0.14 | ||
| Median (min, max) | 44.3 (21–320) | 52.7 (28.3–401) | |
| Platelet Count (×109/L) | |||
| Median (min, max) | 210 (133–301) | 298 (124–322) | 0.33 |
| International normalized ratio | 0.73 | ||
| Median (min, max) | 0.9 (0.7–1.2) | 1.2 (0.9–1.3) | |
| Site of liver biopsy * | 1.0 | ||
| Right lobe | 17 (62.9%) | 19 (61.2%) | |
| Left lobe | 10 (37.1%) | 12 (38.8%) | |
| Liver segments * | p value: 0.89 | ||
| II | 4 | 5 | |
| III | 6 | 7 | |
| IV | 5 | 5 | |
| V | 5 | 6 | |
| VI | 6 | 6 | |
| VII | 0 | 1 | |
| VIII | 1 | 1 | |
| EUS Needle | -- | ||
| 19G FNA | 29 | -- | |
| 25G ProCore® | 1 | ||
| 22G SharkCore® | 8 | ||
| 25G SharkCore® | 11 | ||
| 25G Acquire® | 5 |
Values are expressed as number (percentage) or median (interquartile ranges) where specified; * Patients with focal lesions; Abbreviations: EUS, Endoscopic Ultrasound; IQR, Interquartile Range.